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Available online 28 January 2016Isolation of peptide-speciﬁc T-cell clones is highly desirable for determining the role of T-cells in human disease,
as well as for the development of therapies and diagnostics. However, generation of monoclonal T-cells with the
required speciﬁcity is challenging and time-consuming. Here we describe a library-based strategy for the simple
parallel detection and isolation of multiple peptide-speciﬁc human T-cell clones from CD8+ or CD4+ polyclonal
T-cell populations. T-cells were ﬁrst ampliﬁed by CD3/CD28 microbeads in a 96U-well library format, prior
to screening for desired peptide recognition. T-cells from peptide-reactive wells were then subjected to
cytokine-mediated enrichment followed by single-cell cloning, with the entire process from sample to validated
clone taking as little as 6 weeks. Overall, T-cell libraries represent an efﬁcient and relatively rapid tool for the
generation of peptide-speciﬁc T-cell clones, with applications shown here in infectious disease (Epstein–Barr
virus, inﬂuenza A, and Ebola virus), autoimmunity (type 1 diabetes) and cancer.
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Classical CD8+ (cytotoxic) and CD4+ (helper) T-cell subsets scan for
anomalies in the proteome by recognising peptides presented by major
histocompatibility complex class I (MHC-I) and class II (MHC-II)
proteins, respectively, through their heterodimeric αβ T-cell receptors
(TCRs) (Attaf et al., 2015b). The TCR repertoire of a person is clono-
typically diverse (Attaf et al., 2015a), with individual clonotypes
exhibiting peptide cross-reactivity (Wooldridge et al., 2012; Sewell,
2012), thereby enabling the host to combat invading pathogens andadherin-3; 51Cr, chromium-51;
in–Barr virus; ELISA, enzyme-
ed immunospot assay; EN2,
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Immunity, Cardiff University
Hospital of Wales, Heath Park,
. This is an open access article underoccasionally neoplasms. T-cells can also play a detrimental role in host
health, as is seen during autoimmune disease (Gomez-Tourino et al.,
2015; Salou et al., 2015) and organ transplant rejection (Lin et al., 2015).
T-cell clones provide a good experimental system to address re-
search hypotheses without the ambiguities associated with polyclonal
populations of T-cells, and also enable production of monoclonal T-cell
receptors (TCRs) for immunotherapy approaches. However, generation
of T-cell clones can be challenging,with factors such as sample availabil-
ity, clonotype frequency, and access to suitable detection systems all im-
pinging on the isolation of desired peptide-speciﬁc T-cell populations.
Here we describe a library-based strategy for the relatively rapid
generation of peptide-speciﬁc human T-cell clones from polyclonal
populations of CD8+ or CD4+ T-cells. Firstly, CD3/CD28 microbeads
were used to amplify the T-cells (Trickett and Kwan, 2003) in a 96U-
well library format, fromwhich theywere subsequently screened for re-
activity against desired peptides via enzyme-linked immunospot assay
(ELISpot). T-cells from peptide-reactive wells were then enriched
using cytokine-mediated strategies, subjected to single-cell cloning,
and grown to sufﬁcient numbers for functional validation, with the en-
tire process from blood to validated clone taking as little as 6weeks.We
have now used this T-cell library approach to generate many hundreds
of different T-cell clones, without the need for access to peptide-MHC
(pMHC)multimers or autologous dendritic cells (DCs). Ourmethodolo-
gy is not only compatible with small sample sizes (e.g. 1ml of blood or a
small biopsy), but also permits the isolation of potentially rare T-cellthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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libraries represent a simple and efﬁcient tool for the simultaneous de-
tection and isolation of multiple peptide-speciﬁc T-cell clones, with ex-
amples shown here for infectious disease (Epstein–Barr virus, inﬂuenza
A, and Ebola virus), autoimmunity (type 1 diabetes) and cancer.
2. Materials and methods
2.1. T-cell subset isolation
Buffy coats from healthy human leukocyte antigen (HLA)-A*0201+
(HLA-A2+) donors were obtained from the Welsh Blood Service.
Peripheral blood was obtained from a healthy HLA-DRB*0101+ (HLA-
DR1+) donor, an HLA-A2+ donor with type 1 diabetes (T1D), and a
healthy HLA-A2+ donor who had previously participated in a clinical
trial for an Ebola virus (EBOV) DNA vaccine (EBODNA012-00-VP)
(Martin et al., 2006). Informed consent was obtained from all donors,
and blood was collected according to institutional guidelines. Isolation
of peripheral blood mononuclear cells (PBMC) was carried out by den-
sity gradient centrifugation. On day 1 of the described method, T-cells
were enriched from fresh or frozen PBMC by positive selection with
anti-CD8+ or -CD4+ microbeads, according to the manufacturer's in-
structions (Miltenyi Biotec, Bergisch Gladbach, Germany).
2.2. Tumour lines and immortalised cell lines
All HLA-A2+ tumour lines (Mel 624, Mel 526, MM909.24 andMCF-7)
were maintained in culture at 37 °C as adherent monolayers with R10
media (RPMI 1640 medium supplemented with 10% foetal bovine
serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-
Glutamine (Life Technologies, Paisley, UK)). T2 cells expressing either
HLA-A2 (T2) or T2 cells transduced with HLA-DR1 (T2-DR1s) were cul-
tured at 37 °C as suspension cells in R10.
2.3. Production of HLA-DR1 expressing T2 cells
HLA-DR1was cloned into the pRRLSIN.cPPT.PGK-GFP.WPRE transfer
vector (Addgene #12252). Integrase proﬁcient lentivirus stocks were
produced by co-transfecting 293T/17 cells via calcium phosphate pre-
cipitation with the transfer vector and packaging plasmids: pCMV-
dR8.74 (Addgene #22036) and pMD2.G (Addgene #12259). Lentivirus
containing supernatant was collected after 24 h and 48 h incubations.
The lentivirus stocks were concentrated by ultracentrifugation before
being used to transduce T2 (174 × CEM) cells. The surface expression
of DR1 was assessed using a mouse anti-human unconjugated HLA-DR
antibody (clone L243, 0.5 mg/ml; Biolegend®, London, UK) and a goat
anti-mouse polyclonal conjugated antibody (BD Biosciences, Oxford,
UK). Populations were then enriched using the above antibodies and
anti-ﬂuorochrome microbeads (Miltenyi Biotec). Monoclonal popula-
tions were generated by single-cell cloning of the HLA-DR1 enriched
population.
2.4. Establishing CD8+ and CD4+ T-cell libraries
An overview of our T-cell library methodology is illustrated in Fig. 1.
Following enrichment from PBMC on day 1, T-cells were immediately
seeded (range of densities tested from300 to 1500 cells perwell) across
multiple (typically 1 to 6) 96U-well plates with Human T-Activator
CD3/CD28 Dynabeads® (Life Technologies) (Trickett and Kwan, 2003)
at a 1:2 cell:bead ratio, in 20 IU IL-2 T-cell media (R10 media supple-
mented with 1X MEM non-essential amino acids, 1 mM sodium pyru-
vate, 10 mM HEPES buffer (Life Technologies), and 20 IU/ml IL-2
(aldesleukin, brand name Proleukin®; Prometheus, San Diego, CA). Li-
brary plates were spun before culture at 300 G for 5 min, and then
maintained (at 37 °C) by feeding on days 3 and 6 with 20 IU and
200 IU IL-2 T-cell media, respectively. From day 9 onwards, librarieswere maintained by feeding every 3 days with 200 IU IL-2 T-cell
media (+25ng/ml IL-15 (PeproTech, RockyHill, NJ) for CD8+ libraries).
Between days 14 and 17 of culture, 3 random wells from each library
plate were counted to establish an average T-cell number per well.
Using this representative count, enough cells were removed from each
library well to provide approximately 2.5 × 104 cells per well for an
ELISpot screen. These cells were rested in 96U well plates by washing
in R0 (recipe as for R10 but with no serum), and then culturing for
24 h in R5 (recipe as for R10 but with 5% FBS). Rested library cells
were then screened ± peptide(s) (10−5 to 10−6 M) via ELISpot, using
5 × 104 antigen presenting cells (APC) (T2 or T2-DR1s) per well. This
relatively high level of peptide was used in order to ensure capture of
all responses, although the use of 10−7 and 10−8Mpeptide alsoworked
well (data not shown).Wewere concerned that the use of high concen-
trations of peptide for screening might result in the generation of T-cell
clones that were only capable of recognising targets displaying high
densities of cognate peptide. These worries were unfounded as the
clones generated by this method were often capable of recognising
lower levels of peptide, as demonstrated by the peptide titration data
in the relevant ﬁgures. ELISpot screens were carried out according to
the manufacturer's instructions (Mabtech, Nacka, Sweden), and an
AID ELISpot reader (AID, Strassberg, Germany) was used to read the
number of spot forming cells (SFC) present in each well. If the limit of
detection was exceeded, and individual spots could not be accurately
discerned by the reader, peptide-reactive wells were enumerated by
eye. Cells from peptide-reactive wells of the screen, with a SFC increase
of ≥20 from the corresponding “no peptide”well, were either pooled or
kept as individual wells.
2.5. Isolating T-cell clones
Peptide-speciﬁc (IFNγ or IFNγ/TNFα secreting) T-cells were isolated
from the positive library well(s) by resting the cells in R5 media (as
above), stimulating the rested cells with 10−5 M peptide for 4 h, and
then using an IFNγ or dual IFNγ/TNFα capturemethod to isolate the ac-
tivated T-cells, according to the manufacturer's instructions (Miltenyi
Biotec). The cells were then cloned to the single-cell level by dilution,
or expanded as anenriched line. T-cell clones and linesweremaintained
at 37 °C in either 20 IU or 200 IU IL-2 T-cell media (+IL-15 for CD8+
cells). T-cells were stimulated fortnightlywith 1 μg/ml phytohemagglu-
tinin (PHA) (Alere, Cheshire, UK), in the presence of irradiated
(3100 Gy) allogeneic feeder cells (PBMC) from three healthy donors
(5 × 104 per well).
2.6. Peptides
The peptides and their knownHLA restriction are listed in Table 1. In
addition to generating T-cell clones speciﬁc for established T-cell
epitopes, we were also interested in using the technique to verify new
epitopes. In this respect, we used the T-cell library strategy to test
new peptide epitopes from Engrailed-2 (EN2) (Morgan et al., 2011),
inﬂuenza A (ﬂu) haemagglutinin (HA) (Babon et al., 2012), and the
5T4 oncofetal protein (Starzynska et al., 1994).
2.7. Clone validation
Peptide-speciﬁcity of the T-cell clones was determined by quantify-
ing either MIP-1β or IFNγ release from peptide-stimulated T-cells in an
enzyme-linked immunosorbent assay (ELISA), according to the
manufacturer's instructions (R&D Systems,Minneapolis,MN). Typically,
6 × 104 APC perwell, 3 × 104 rested T-cells perwell, and 10−5M of pep-
tidewas used for each ELISA. Clone sensitivity (dose–response) was de-
termined by titrating the peptide (ranging from 10−5 M to 10−10 M) in
a MIP-1β ELISA. MIP-1β and IFNγ concentrations were calculated by
subtracting the appropriate “no peptide” control wells. Where possible,
staining with pMHCmultimer (Dolton et al., 2015; Tungatt et al., 2015)
Fig. 1. Overview of T-cell library methodology. (A–C) T-cells were enriched from fresh or frozen peripheral blood mononuclear cells (PBMC) via magnetic separation using anti-CD8+ or
-CD4+microbeads, prior to seeding into multiple 96U-well plates (range tested from 300–1500 cells per well) with CD3/CD28 beads at a 1:2 cell:bead ratio. (D) Approximately 2 weeks
after initial T-cell activation with the beads, libraries were screened ± peptide(s) by IFNγ enzyme-linked immunospot assay (ELISpot). (E & F) Peptide-reactive wells identiﬁed from the
screenwere then enriched for peptide-speciﬁc T-cells using either an IFNγ or dual IFNγ/TNFα capturemethod. (G) T-cells were then cloned to the single-cell level * or expanded as a line.
(H) Clone validation was performed by peptide titration (dose–response), phenotyping, pMHC multimer staining, clonotyping and cytotoxicity assays.
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the case of tumour-speciﬁc clones, a chromium (51Cr)-release cytotox-
icity assay (Tungatt et al., 2015) (PerkinElmer, Waltham, MA) was car-
ried out to determine if the T-cell clones were capable of tumour cell
killing. Percentage (%) speciﬁc lysis was calculated using the following
equation: (experimental release− spontaneous release) / (maximal re-
lease− spontaneous release) × 100.
3. Results
3.1. Generation of a T1D-relevant CD8+ T-cell clone from limited
starting material
One of the main challenges in identifying and isolating peptide-
speciﬁc T-cells frompatients is that there is often limited cell availability
due to sample sharing between researchers, ethical limitations on the
size/volume of the sample that can be taken, and also the nature of
the tissue source, such as with biopsies. To demonstrate that T-cell li-
braries can be used to overcome this limitation, 1 ml of blood from an
HLA-A2+ donor with T1D was used to make a library consisting of 96
wells with 1000 CD8+ T-cells per well. After 14 days, and an approxi-
mate 300- to 400-fold expansion of T-cells, the library was screenedagainst two pools of HLA-A2-restricted peptides using IFNγ ELISpot.
Peptides from Epstein–Barr virus (EBV) (BMFL1280–288 (Steven et al.,
1997)) and ﬂu (matrix protein (MP)58–66 (Bednarek et al., 1991))
were used to test the feasibility of screening in this manner, as robust
T-cell responses are elicited in HLA-A2+ people exposed to these virus-
es. Background release of IFNγwithout added peptide was observed in
some wells (Fig. 2A, top), however this did not preclude the identiﬁca-
tion of peptide-reactive wells: 30wells of the 48 screened (17/48) were
positive for the EBV peptide, and 2/48 for the ﬂu peptide (Fig. 2A, mid-
dle). More interestingly, 1/96 of the wells screened with a pool of four
well-characterised T1D-relevant peptides (preproinsulin (PPI)15–24
(Skowera et al., 2008), insulin β chain (InsB)10–18 (Pinkse et al., 2005),
glutamic acid decarboxylase (GAD65)114–123 (Panina-Bordignon et al.,
1995), and islet-speciﬁc glucose-6-phosphatase catalytic subunit-
related protein (IGRP)265–273 (Jarchum et al., 2008)) was peptide-
reactive (Fig. 2A, bottom). One peptide-reactive well from each of the
three screens was enriched based on IFNγ production in response to
stimulation with relevant peptide(s), prior to T-cell cloning. pMHC
tetramer staining was used to conﬁrm the speciﬁcities of the EBV and
ﬂu clones (Fig. 2B). We established that the T1D peptide-reactive
clone (GD.InsB.4)was speciﬁc for the InsB peptide, as shown via peptide
dose–response (MIP-1β ELISA) and pMHC dextramer staining (Fig. 2C).
Table 1
List of peptides used in this study. HLA restriction and full peptide sequence are listed in all but 3 cases. Sequences of the newHLA-A*0201-restricted Engrailed-2-derived epitopes, and the
new HLA-DRB*0101-restricted epitopes from inﬂuenza haemagglutinin and 5T4 oncofetal protein will be published in other studies we are currently preparing.
Origin Protein
Amino acid
residues
Peptide
sequence
HLA
restriction
Reference
Epstein–Barr virus BMLF1 lytic protein 280–288 GLCTLVAML A*0201 Steven et al. (1997)
Inﬂuenza A Matrix protein (MP) 58–66 GILGFVFTL A*0201 Bednarek et al. (1991)
Inﬂuenza A Haemagglutinin (HA) Putative DRB*0101 Babon et al. (2012)
Zaire Ebola virus Nucleoprotein 150–158 FLSFASLFL A*0201 Sundar et al. (2007)
Zaire Ebola virus Nucleoprotein (NP) 202–210 RLMRTNFLI A*0201 Sundar et al. (2007)
Zaire Ebola virus Nucleoprotein 404–412 KLTEAITAA A*0201 Sundar et al. (2007)
Type 1 diabetes Glutamic acid decarboxylase (GAD65) 114–123 VMNILLQYVV A*0201 Panina-Bordignon et al. (1995)
Type 1 diabetes Insulin β chain (InsB) 10–18 HLVEALYLV A*0201 Pinkse et al. (2005)
Type 1 diabetes Islet-speciﬁc glucose-6-phosphatase catalytic subunit-related protein (IGRP) 265–273 VLFGLGFAI A*0201 Jarchum et al. (2008)
Type 1 diabetes Preproinsulin (PPI) 15–24 ALWGPDPAAA A*0201 Skowera et al. (2008)
Tumour Cadherin-3/P-Cadherin (CDH3) 655–663 FILPVLGAV A*0201 Imai et al. (2008)
Tumour Engrailed-2 (EN2) Putative A*0201 Morgan et al. (2011)
Tumour Glycoprotein 100 (gp100) 280–288 YLEPGPVTA A*0201 Kawakami et al. (1995)
Tumour Insulin-like growth factor 2 mRNA binding protein 3 (IMP-3) 199–207 RLLVPTQFV A*0201 Tomita et al. (2011)
Tumour Melanoma-associated antigen-1 (MAGE-A1) 278–286 KVLEYVIKV A*0201 Pascolo et al. (2001)
Tumour Melanoma-associated antigen-3 (MAGE-A3) 112–120 KVAELVHFL A*0201 Chinnasamy et al. (2011)
Melanoma-associated antigen 3 (MAGE-A3) 240–248 YLEYRQVPG A*0201 Graff-Dubois et al. (2002)
Tumour NY-BR-1 904–912 SLSKILDTV A*0201 Wang et al. (2006)
Tumour Oncofetal protein, 5CT4 Putative DRB*0101 Starzynska et al. (1994)
Tumour Prostatic acid phosphatase-3 (PAP-3) 299–307 ALDVYNGLL A*0201 Harada et al. (2003)
Tumour Prostein 31–39 CLAAGITYV A*0201 Kiessling et al. (2004)
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β chain antibody (data not shown), suggesting they were likely to be
derived from the same precursor. Together, these data verify that
peptide-speciﬁc T-cells of interest can be successfully isolated from
patient samples even when cells are in short supply.
3.2. Generation of tumour-speciﬁc T-cell clones from potentially rare
populations using CD8+ T-cell libraries
In addition to the limitations associated with sample size, the pro-
duction of T-cell clones is often made more difﬁcult when the peptide-
speciﬁc T-cells of interest occur at naturally low frequencies. This is
often the case with tumour-reactive T-cells (Sharpe and Mount, 2015)
(recognising tumour-associated antigens) in PBMC, as a result of thymic
selection reducing the presence of “self” reactive T-cells in the pe-
riphery (Klein et al., 2014). Thus, with the aim of isolating rare
tumour-speciﬁc T-cells, a CD8+ T cell library (576 wells at 1000
cells per well) was generated from the PBMC of a healthy HLA-A2+
donor, and screened via IFNγ ELISpot against a pool of ﬁve HLA-A2-
restricted tumour peptides (melanoma-associated antigen-3
(MAGE-A3)112–120 (Chinnasamy et al., 2011), MAGE-A3240–248
(Graff-Dubois et al., 2002), cadherin-3/P-cadherin (CDH3)655–663
(Imai et al., 2008), NY-BR-1904–912 (Wang et al., 2006) and glycopro-
tein 100 (gp100)280–288 (Kawakami et al., 1995)). Fig. 3A shows the
positive library wells (10/576) from this library screen, which were
subsequently pooled, and speciﬁcity for the gp100 peptide deter-
mined (by IFNγ ELISpot) prior to enrichment and cloning (Fig. 3B).
From this library, a gp100-speciﬁc clone (THEAK.gp100) was pro-
duced, and its reactivity conﬁrmed via a peptide dose–response ex-
periment using MIP-1β ELISA (Fig. 3C). THEAK.gp100 was able to
kill multiple HLA-A2+ melanoma cell lines (Mel 624, Mel 526 and
MM909.24) in a 51Cr-release assay after 18 h, at a T-cell:tumour
cell ratio of 10:1 (Fig. 3D).
Next, a second CD8+ T-cell library (288 wells at 500 cells per well)
was produced from a different healthy HLA-A2+ donor, but this time
screened against two separate pools of HLA-A2-restricted tumour pep-
tides, (Pool 1: prostatic acid phosphatase-3 (PAP-3)299–307 (Harada
et al., 2003), melanoma-associated antigen-1 (MAGE-A1)278–286
(Pascolo et al., 2001), MAGE-A3112–120, prostein31–39 (Kiessling et al.,
2004), insulin-like growth factor 2 mRNA binding protein 3 (IMP-3199–207) (Tomita et al., 2011), and CDH3655–663; Pool 2: six putative
peptides from EN2 (EN2-1, -2, -3, -4, -5, and -6)). ELISpot data for the
peptide-reactive wells (1/288 for pool 1, and 13/288 for pool 2) is
shown in Fig. 3E. T-cells were then cloned from the positive wells, and
screened against individual peptides by IFNγ ELISA (Fig. 3F). Two clones
were produced; one recognising the CDH3 peptide (GD.FIL.6/30), and
the other recognising a putative EN2-3 peptide (GD.RPA.2/30), as con-
ﬁrmed by a peptide dose–response (MIP-1β ELISA) (Fig. 3G). The
CDH3-speciﬁc clone was shown to speciﬁcally kill an HLA-A2+ breast
cancer cell line (MCF-7), and not an HLA-A2+ metastatic melanoma
cell line (MM909.24; obtained from the Center for Cancer Immune
Therapy, Herlev Hospital, Copenhagen, Denmark) in a 51Cr-release
assay after 4 h (Fig. 3H). Collectively, these data show that obtaining
tumour-reactive T-cell clones using this method is not hindered by pre-
dicted low clonotype frequencies.
3.3. Generation of T-cell clones from CD4+ T-cell libraries
To further illustrate the versatility of the T-cell library method, a
CD4+ T-cell library (192 wells at 1000 cells per well), was generated
from a healthy HLA-DR1+ donor, and simultaneously screened via
IFNγ ELISpot for reactivity against two HLA-DR1-restricted peptide
pools. The ﬁrst peptide pool contained three putative peptides from
HA of ﬂu (Flu-1, -2, and -3), and the second peptide pool contained
ﬁve putative peptides from 5T4 oncofetal protein (5T4-2, -12, -20, -38,
and -PMS). Positive wells from the screen (3/48 for the ﬂu pool, and
9/144 for the 5T4 pool: shown in Fig. 4A) were enriched based on
IFNγ production in response to peptide(s), and then expanded once
with PHA and irradiated allogeneic feeder cells to produce lines. The
lines were subsequently screened against individual peptides in an
IFNγ ELISpot (Fig. 4B), and then cloned to the single-cell level. From
this, three 5T4-clones (GD.C112.DC, GD.D821.DC and GD.D104.DC)
were generated and tested against decreasing doses of peptide via
MIP-1β ELISA, in order to establish their sensitivity to the corresponding
epitope (Fig. 4C). Thus, these data indicate that our T-cell library strate-
gy can also successfully produce CD4+ T-cells with desired speciﬁcities.
It is noteworthy that autologous EBV immortalised B-cell lines were ini-
tially used for the screening of CD4+ libraries, but these induced high
numbers of positive wells (data not shown), presumably because of T-
cells with reactivity against EBV.
Fig. 2.Generation of clones that recognise EBV, inﬂuenza A, and insulin β chain peptides from a type 1 diabetes (T1D) CD8+ T-cell library. (A) A CD8+ T-cell library (96 wells at 1000 cells
per well) from an HLA-A2+ donor with T1Dwas screened by IFNγ enzyme-linked immunospot assay (ELISpot), using T2 as antigen presenting cells. Library cells were tested alone (top),
against HLA-A2-restricted peptides from Epstein Barr virus (EBV) (BMFL1280–288) and inﬂuenza A (ﬂu) virus (matrix protein (MP)58–66) (middle), and against a pool of four HLA-A2-
restricted T1D-relevant peptides (preproinsulin (PPI)15–24, insulin β chain (InsB)10–18, glutamic acid decarboxylase (GAD65)114–123 and islet-speciﬁc glucose-6-phosphatase catalytic
subunit-related protein (IGRP)265–273) (bottom). The number of spot forming cells (SFC) per 3.3 × 104 cells, as determined by the ELISpot reader, is shown for each well. Those used
for single-cell cloning following IFNγ enrichment are colour coded (EBV: red, ﬂu: black, T1D: blue). (B) T-cells cloned from the EBV (A, red) and ﬂu (A, black) peptide-reactive wells
were stained with cognate pMHC tetramer. (C) A T-cell clone (GD.InsB.4) from the positive well for the T1D peptide pool (A, blue) was tested against individual peptides (data not
shown), titrated against the InsB peptide in a MIP-1β ELISA (top), and stained with pMHC dextramer assembled with the same epitope (bottom).
47S.M. Theaker et al. / Journal of Immunological Methods 430 (2016) 43–503.4. Generation of Zaire Ebola virus (EBOV-Z)-speciﬁc T-cell clones from a
vaccinated donor
Finally, we reasoned that this method of T-cell clone generation
could also be used to generate peptide-speciﬁc T-cell clones from vacci-
nated individuals. Therefore, a CD8+ T cell library (192 wells at 1000cells per well) was generated from the PBMC of a healthy HLA-A2+
donor, who had previously participated in a clinical trial for an EBOV
DNA vaccine. The library was screened via IFNγ ELISpot for reactivity
against a pool of three predicted HLA-A2-restricted EBOV-Z nucleopro-
tein (NP) epitopes (EBOV-Z-NP150–158, EBOV-Z-NP202–210, and EBOV-Z-
NP404–412) (Sundar et al., 2007) (Fig. 4D). Positive wells from the screen
Fig. 3. CD8+ T-cell clone generation from T-cell libraries screened with tumour peptides. A CD8+ T-cell library (576wells at 1000 cells per well) from an HLA-A2+ donor was screened±
an HLA-A2-restricted tumour peptide pool by IFNγ enzyme-linked immunospot assay (ELISpot), using T2 as antigen presenting cells. (A) Spot forming cells (SFC) per 2.5 × 104 cells is
shown for the 10 peptide-reactive wells. (B) Positive wells were then pooled, and tested for individual peptide-speciﬁcity by IFNγ ELISpot. SFC per 2.5 × 104 cells for each well is
shown (SFC for duplicate wells has been shown in brackets). The pooled cells were then enriched for reactive T-cells based on IFNγ production, and subjected to single-cell cloning. (C
& D) One of the clones (THEAK.gp100) was speciﬁc for the gp100-derived peptide by MIP-1β ELISA, and also successfully killed multiple HLA-A2+ melanoma cell lines (Mel 624, Mel
526, and MM909.24) in a 51Cr-release assay after 18 h, at a T-cell:tumour cell ratio of 10:1. A library from a second HLA-A2+ donor (288 wells at 500 cells per well) was screened as in
(A), but with two pools of HLA-A2-restricted tumour peptides. (E) SFC per 5 × 104 cells for the 14 peptide-reactive wells. (F) Cloned T-cells were screened against individual peptides
by IFNγ ELISA, and were found to recognise a peptide from either cadherin-3 (CDH3) or Engrailed-2 (EN2). (G) Both the CDH3-speciﬁc clone (GD.FIL.6/30) and EN2-3-speciﬁc clone
(GD.RPA.6/2) were tested for sensitivity to cognate peptide by MIP-1β ELISA. (H) The GD.FIL.6/30 clone was also tested for cytotoxicity towards an HLA-A2+ breast cancer cell line
(MCF-7), and an HLA-A2+ metastatic melanoma cell line (MM909.24) in a 51Cr-release assay after 4 h.
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then cloned to the single-cell level. Six EBOV-Z-speciﬁc clones were
generated, all reactive to the EBOV-Z-NP150–158 peptide, as determined
by MIP-1β ELISA (Fig. 4E). Peptide dose–response curves (MIP-1β
ELISA) for three of the clones (ST3.ebola.FLS, ST13.ebola.FLS, and
ST17.ebola.FLS) are shown as an example (Fig. 4F). These data demon-
strate the ability of this T-cell library method to rapidly produce viral-
speciﬁc T-cell clones from the blood of a vaccinated donor.
4. Discussion
Modern advances in cell sorting, using ﬂuorescence or magnetic
beads, have allowed the generation of T-cell clones following physicalisolation with pMHC multimers, or functional detection using antibod-
ies speciﬁc for cellular activation markers. Although these techniques
have worked well in our laboratory for some antigens, we have failed
to grow robust clones using these standard methodologies more often
than we have succeeded. In order to circumvent this difﬁculty, we de-
veloped the T-cell library strategy described here. Previous studies
have applied a T-cell library approach to study T-cell frequencies, but in-
stead used PHA in combination with irradiated allogeneic feeder cells
for T-cell expansion (Campion et al., 2014; Geiger et al., 2009). The
CD3/CD28 beads used in our strategy have been shown to better pre-
serve the TCR repertoire during in vitro expansion (Neller et al., 2012).
Nevertheless, while this methodology maintains the general TRBV
families and dominant antigen-speciﬁc T-cell responses faithfully, it
Fig. 4. Isolation of peptide-speciﬁc CD4+ T-cells, and Zaire Ebola virus (EBOV-Z) speciﬁc CD8+ T-cells from T-cell libraries. T-cell libraries (192wells per library at 1000 cells perwell)were
established from a healthy HLA-DR1+ donor (A–C), and a healthyHLA-A2+ donor who had previously participated in an EBOVDNA vaccine trial (D–F). (A) The healthyHLA-DR1+ library
was screened by IFNγ enzyme-linked immunospot assay (ELISpot) against twopools of peptides, using T2-DR1s as antigen presenting cells (APC). Spot forming cells (SFC) per 5× 104 cells
are shown for the peptide-reactive wells. 3 wells were positive for the inﬂuenza A (ﬂu) pool (three putative peptides from haemagglutinin: Flu-1, -2 and -3), and 9wells were positive for
the 5T4 oncofetal protein pool (ﬁve putative peptides: 5T4-2, -12, -20, -38 and -PMS). 3 of the positive library wells (C11, D8 and D10), shown to respond to different 5T4 peptides, have
been colour coded to illustrate their progression to validated 5T4-speciﬁc clones (B). Peptide dose–responses for the T-cell clones grown from these wells (GD.C112.DC, GD.D821.DC and
GD.D104.DC)have been illustrated in (C). (D) A second library established fromahealthyHLA-A2+EBOV vaccinated individualwas screened by IFNγ ELISpot, using T2 cells asAPC. SFC per
3 × 104 cells has been shown for the peptide-reactivewells. 2wells showed a positive response to the pool of three HLA-A2-restricted epitopes (EBOV-Z-NP150–158, EBOV-Z-NP202–210, and
EBOV-Z-NP404–412) from EBOV-Z nucleoprotein (NP). These wells were pooled, subjected to IFNγ/TNFα dual enrichment, and then cloned to the single-cell level. (E) All six clones
generated a response to EBOV-Z-NP150–158 peptide. Dose–response curves (MIP-1β ELISA) for three of these clones (ST3.ebola.FLS, ST13.ebola.FLS and ST17.ebola.FLS) are depicted in (F).
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sion phase.
Using the methodology we describe here, we have been able to si-
multaneously generatemanyhundreds of peptide-speciﬁc T-cell clones,
with at least one being grown from each library. T-cell libraries have be-
come themethod of choice for generatingmonoclonal T-cells in our lab-
oratory, as they avoid the need for pMHC multimers, ample donor
material, or time-consuming DC production. Furthermore, we consider
it an advantage to have the T-cells already adapted to in vitro culture
prior to screening, and also to avoid repeated exposure to antigenic pep-
tide, which can often lead to T-cell exhaustion (Wherry and Kurachi,
2015). Importantly, we have found T-cell clones to be extremely advan-
tageous for improving pMHCmultimer staining protocols (Dolton et al.,
2015; Tungatt et al., 2015), T-cell epitope identiﬁcation, deﬁning T-cell
cross-reactivity (Wooldridge et al., 2012), obtaining monoclonal TCRs
(for genetic, biophysical and structural studies), and peptide vaccine de-
velopment (Ekeruche-Makinde et al., 2012).
In summary, we have developed an efﬁcient and reproducible
library-based strategy for the successful detection and isolation of
peptide-speciﬁc human T-cell clones from polyclonal CD8+ or CD4+
T-cell populations. By introducing a degree of clonality at the start of
culture, and by coupling this with effective cytokine-mediated en-
richment strategies, our methodology permits the relatively rapidgeneration of fully validated clones in as little as 6 weeks. Overall, T-
cell libraries provide a useful tool for the T-cell immunologist, as
they can be used for the simple parallel generation of multiple T-
cell clones with numerous research applications in infectious dis-
ease, autoimmunity and cancer.
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